The committee once again considered the pricing of KEYTRUDA for lung cancer at the meeting over an issue that emerged in mid-2018 - and the company is still giving no indication it will accept a reduction.

Latest Video
New Stories
-
Medicines Australia backs focus on listings and productivity in government brief
July 3, 2025 - - Latest News -
AusBiotech seeking a head of investment to drive sector growth
July 3, 2025 - - Australian Biotech -
What's the point of pretending that Australia doesn't free-ride on US innovation?
July 3, 2025 - - Latest News -
Framework pushes genomics funding to a review that is mostly silent on it
July 3, 2025 - - Latest News -
Draft 'National Health Genomics Policy Framework' out for consultation
July 3, 2025 - - Latest News -
MedAdvisor announces agreement confirming the sale of Australian business
July 3, 2025 - - Latest News -
GBMA announces planned departure of long-standing CEO
July 2, 2025 - - Latest News